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In DNA cotransfection experiments, the Epstein-Barr virus immediate-early gene product, BMLF1,
stimulated the chloramphenicol acetyltransferase (CAT) activity of both latent and productive EBV promoters
linked to CAT. This BMLF1-induced increase in CAT activity was out of proportion to the effect on CAT
mRNA, suggesting a posttranscriptional mechanism. Furthermore, when growth hormone was used as a
reporter gene instead of CAT, BMLF1 no longer functioned. Thus, the BMLF1 effect was reporter-gene
dependent. The effect of the BMLF1 gene product does not then appear to be directed at promoter activation,
but instead may function to increase the level of an as yet unidentified protein(s) required for Epstein-Barr
virus infection.
A biologic hallmark of Epstein-Barr virus (EBV) infection,
as with other herpesviruses, is latency (10, 27). The mecha-
nisms governing latency are still obscure, but it is likely that
control of viral gene expression is critical. The availability of
latently infected, EBV-transformed B-cell lines provides the
opportunity to study herpesviral gene regulation in a latent
system and to examine factors important in disrupting la-
tency.
Few viral genes are transcribed in latent EBV infection
(26, 43). The most important latent gene products identified
so far are Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2,
and the latent membrane protein (LMP) (12, 17-19, 25, 34,
36, 44, 47). The EBNA-1 gene product encodes a transacti-
vating function which is crucial in maintaining episomal
replication during latent infection (36, 47). In productive
EBV infection, which can be induced from the latent state in
vitro by various inducers (31, 34), many more genes are
transcribed, including three EBV immediate-early (IE) genes
(4, 39) (BZLF1, BRLF1, and BMLF1) whose products have
been shown to encode transactivating functions (6, 7, 15, 16,
21, 23, 30, 41, 45). At least one of these IE gene transacti-
vators, BZLF1, clearly plays a crucial role in the disruption
of latency and activation of viral replication (15, 41). The
BZLF1 gene product has been shown to stimulate the
activity of several different EBV promoters (6, 7, 16),
including the BMLF1 promoter (20a, 21).
The role of the BMLF1 IE gene product in EBV infection
is less clear. The BMLF1 gene product appears to transac-
tivate several different promoters when linked to the heter-
ologous chloramphenicol acetyltransferase (CAT) gene (6,
30, 45). We reported recently that the BMLF1 gene product
can increase CAT activity directed by the human immuno-
deficiency virus promoter (22) and demonstrated that the
mechanism of transactivation by BMLF1 may be at least
partly posttranscriptional, since the steady-state level of
human immunodeficiency virus-CAT mRNA was not af-
fected to the extent that CAT activity was increased.
In this report, we have examined the effect of the BMLF1
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gene product on latent versus productive EBV promoters.
Representative EBV promoters were chosen for study:
latent (latent membrane protein and the BamHI-W and
BamHI-C EBNA promoters [5, 29, 37]), IE (BMLF1 [38]
and BZLF1 [4]), early (the early antigen diffuse gene,
BMRF1 [8, 38]), and late (the major envelope glycoprotein,
gp350/220 [2]). We show that cotransfection of each of the
EBV-CAT contructs with the BMLF1 construct results in
increased CAT activity. As in our previous report, the
increase in CAT activity produced by BMLF1 is not accom-
panied by a significant increase in steady-state-level CAT
mRNA (22). However, we now demonstrate that the
BMLF1 transactivation effect is reporter-gene limited. Al-
though the activity of the different promoters linked to the
CAT gene is increased by cotransfection with BMLF1,
several of the same promoters linked to the human growth
hormone gene are not transactivated. We present here the
evidence that the ability of the BMLF1 gene product to
transactivate CAT vectors appears to be posttranscription-
ally mediated and dependent on some quality brought to the
vectors by the CAT gene itself, rather than specific to a
particular class of promoters.
MATERIALS AND METHODS
Cell lines. Loukes is an EBV-negative Burkitt's lymphoma
B-cell line, Raji is a latently infected EBV-positive Burkitt's
lymphoma B-cell line, and B95-8 is a virus-producing EBV-
positive marmoset B-cell line. Jurkat, a T-cell line, the
human cervical epithelial cell line HeLa, and a human
glioblastoma multiforme line, U-373-MG, were also used.
Lymphoid cell lines were maintained in RPMI medium with
10% fetal calf serum. The monolayer cells were maintained
in minimal essential medium with 5% fetal calf serum.
DNA transfections. Plasmid DNA was purified through two
sequential cesium chloride gradients. Electroporation into
lymphoid cells (42) was accomplished at 1,500 V with a
Zapper electroporation unit from the University of Wiscon-
sin Medical Electronics Shop, Madison; 107 lymphoid cells
were transfected per condition for each CAT assay. Each of
the lymphoid lines had an approximately 30 to 50% cell
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FIG. 1. Construction of seven EBV promoter-containing plasmids. The promoter regions of selected EBV genes were excised from the
EBV genome and ligated into the BglII site of vector pCAT3M (29). The vector contains the bacterial CAT gene and an SV40 polyadenylation
site, but no eucaryotic promoter element. Restriction sites were chosen based on previously published 5' mRNA start sites for each gene (2,
4, 5, 8, 20, 30, 38). Three promoters expressed during latent infection (the BamHI-C and -W EBNA promoters and the latent membrane
protein promoter), two promoters of IE genes (BZLF1 and BMLF1), one early promoter (BMRF1), and one promoter of a late gene
(gp350/220) were chosen for study. An additional plasmid, pS-CAT (not shown), was constructed which contains the entire BamHI S fragment
(and hence the BMLF1 promoter) linked to CAT.
survival rate under these electroporation conditions. HeLa
cells were transfected with the DNA-calcium phosphate
coprecipitation method as described previously (14).
Plasmid constructions. (i) EBV-CAT plasmids. EBV pro-
moter sequences were ligated into the BglII site of plasmid
pCAT3M. Plasmid pCAT3M (a gift from the late George
Khoury) contains the CAT gene and a simian virus 40 (SV40)
polyadenylation site, but no eucaryotic promoter element
(29). The exact genome map locations (1) of the EBV
promoter inserts are shown in Fig. 1. The sequences cloned
into the CAT expression vector were based on previously
published 5' mRNA start sites (2, 4, 5, 8, 20, 30, 32, 38) and
the EBV sequence (1). Seven different EBV-CAT plasmids
were constructed: three latent EBV promoters, two IE
promoters, and one early and one late promoter were chosen
for study. The pC-CAT and pW-CAT constructs place two
different putative EBNA promoters (5, 37) (from BamHI-C
and BamHI-W) in front of the CAT gene. The pLMP-CAT
plasmid has the promoter region of the latent membrane
protein. The pZ-CAT and pM-CAT constructs contain the
upstream regions of the two different EBV IE genes BZLF1
and BMLF1. An additional plasmid, pS-CAT (not shown),
was also constructed which contains the entire BamHI S
fragment (and hence the BMLF1 promoter) linked to CAT.
The pEA-CAT construct contains the BMRF1 promoter of
the early antigen diffuse gene. The pLate-CAT construct
contains the suspected promoter region of the late gene
encoding the two major outer envelope glycoproteins gp350/
220. We have confirmed the use of the expected 5' start site
in the pC-CAT and pS-CAT constructs; the other mRNA
start sites are presumed from the work of previous investi-
gators and the EBV sequence (1).
(ii) Plasmid expressing the BMLF1 gene product. We con-
structed plasmid pEBV-MIE (22) to place the BMLF1 gene
product under the control of a strong promoter. To create
pEBV-MIE, the 3.0-kilobase BamHI-BglII J fragment
(which contains the second exon of BMLF1) was excised
from the pM-B2-J plasmid (35) (a gift from George
Bornkamm) and ligated into the BamHI site of pHD1013 (a
gift from Michelle Davis and E. S. Huang). The pHD1013
plasmid is a pGem-2 (Promega)-based vector which contains
the human cytomegalovirus IE promoter (9). Previous stud-
ies have shown that only the second exon of BMLF1 is
required for transactivating effects (30).
(iii) Growth hormone plasmids. To test for reporter-gene
dependence of the BMLF1 transactivating effect, we con-
structed two plasmids (pM-GH and pC-GH) which insert the
identical EBV promoter sequences contained within pM-
CAT or pC-CAT into the BamHI site of plasmid p4tGH (40).
Vector p¢GH contains the human growth hormone gene and
a polyadenylation site, but has no eucaryotic promoter
element.
CAT assays. Cells were transfected with plasmid DNA,
and 48 h later an extract of the cells was prepared and
incubated at 37°C with 14C-labeled chloramphenicol in the
presence of acetyl coenzyme A, as described previously
(13). The percent acetylation of chloramphenicol was quan-
titated by thin-layer chromatography followed by autoradi-
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ography and scintillation counting. All CAT assays were
repeated with smaller amounts of protein extract if results
were not in the linear range (<70% chloramphenicol acety-
lation).
RNA analysis. An Sp6-generated antisense RNA probe
complementary to the pLate-CAT plasmid was made by
cloning a fragment from pLate-CAT containing the intact
promoter region plus 250 base pairs (bp) of the CAT gene
into the pGem-2 vector (Promega) next to the Sp6 promoter.
Total cellular RNA was prepared 2 days after transfection by
a modification of the Favaloro method (11, 24); then, 35 pLg
was hybridized overnight to the 32P-labeled antisense RNA
probe (6.5 x 104 cpm). The hybrid probe was digested with
Si nuclease (3), and the Si-protected fragment was electro-
phoresed on a 6% acrylamide gel with 7 M urea. Autoradio-
gram bands were analyzed by laser densitometry.
To determine the actual 5' start site(s) in the pS-CAT and
pC-CAT plasmids, we used the primer extension method. A
20-bp oligonucleotide sequence homologous to the CAT
gene in the region either 15 to 34 or 66 to 85 bp downstream
of the ATG codon was synthesized and labeled with [-Y-32P]
ATP. Labeled oligonucleotide (105 counts) was hybridized
overnight with 50 ,ug ofRNA at 30°C in a solution containing
80% formamide, 40 mM PIPES [piperazine-N,N'-bis(2-
ethanesulfonic acid)] (pH 6.4), 400 mM NaCl, and 1 mm
EDTA. Primer extension was then performed at 42°C for 90
min, using avian myeloblastosis virus reverse transcriptase
as described previously (33). After RNase digestion, the
primer extension products were electrophoresed on a 6%
acrylamide-urea gel.
RESULTS
Constitutive activity of EBV promoters in different cell
types. Prior to assessing the effect of the EBV BMLF1 gene
product on the different EBV-CAT constructs, we deter-
mined the constitutive activity of each EBV promoter in a
variety of cell types. In these experiments, the activity of the
EBV-CAT constructs was compared in each cell type with
the activities of the pCAT3M plasmid, which has the CAT
gene without any eucaryotic promoter; the pRSV-CAT
plasmid (13), which has the strong Rous sarcoma virus
promoter; and plasmid pAlOCAT (28), which has the weak
SV40 early promoter (but not enhancer) linked to CAT. The
CAT constructs were transfected into cells, using either
electroporation (lymphoid lines) or the calcium phosphate
technique (HeLa and U-373-MG cells); CAT activity pro-
duced by each plasmid was assayed 2 days later.
The two EBNA promoters, pW-CAT and pC-CAT, each
produced significantly more CAT activity (relative to the
control plasmids pCAT3M and pAlOCAT) in lymphoid ver-
sus nonlymphoid lines (Table 1). In both latently and pro-
ductively infected EBV-positive B-cell lines, the pC-CAT
construct produced more CAT activity than did the pW-CAT
plasmid. The activity of the pLMP-CAT plasmid was quite
weak in all cell lines tested. Other than the strong activity
produced by the pM-CAT plasmid in the productively in-
fected B95-8 cell line, the constitutive activity of the four
productive promoters was also quite weak in all cell lines
tested.
The EBV IE gene product, BMLF1, transactivates each of
the seven EBV-CAT constructs. We next analyzed the effect
of the EBV IE gene product, BMLF1, on the seven different
EBV-CAT constructs. Table 2 shows the results of repre-
TABLE 1. Activity of EBV-CAT plasmids in different cell types
% Acetylation'
Plasmid
Loukes Raji B95-8 Glial HeLa Jurkat
Control
pRSV-CAT 3.7 6.06 12.77 2.2 3.77 6.14
pCAT3M 0.2 0.10 0.34 0.05 0.03 0.11
pA10-CAT 0.1 0.05 0.52 0.06 0.05 0.10
Latent promoters
pW-CAT 0.7 0.36 0.42 0.05 0.03 2.90
pC-CAT 1.8 1.98 2.66 0.04 0.13 2.88
pLMP-CAT 0.1 0.17 0.60 0.04 0.07 0.37
Productive promoters
pZ-CAT 0.2 0.03 0.19 0.08 0.03 0.07
pM-CAT 0.1 0.04 1.55 0.04 0.07 0.05
pEA-CAT 0.1 0.04 0.93 0.05 0.03 0.12
pLate-CAT 0.1 0.04 0.10 0.08 0.04 0.02
" Calculated as percentage of the ratio of counts of acetylated chloramphen-
icol products over total chloramphenicol counts per 10 ,ug of protein extract.
Values represent the averages of at least two experiments in each cell type.
sentative cotransfection experiments done in the EBV-
negative Loukes and the EBV-positive Raji B cells. In either
line, the CAT activity of each of the seven EBV-CAT
constructs was increased after cotransfection with the
TABLE 2. Effect of BMLF1 gene product on different
EBV-CAT constructs
Plasmid Expt ~Fold increase in Avg increasePlasmid CAT activity" ±2 SD
Control




pW-CAT 1 15.3 16.5 ± 1.7
2 15.7
3 18.6
pC-CAT 1 54.3 29.7 ± 20.3
2 14.4
3 20.3




pZ-CAT 1 11.3 6.3 ± 4.1
2 3.5
3 4.0
pM-CAT 1 13.8 16.8 ± 6.3
2 12.1
3 24.5
pEA-CAT 1 12.5 6.3 ± 5.1
2 3.2
3 3.1
pLate-CAT 1 3.8 3.9
2 4.0
"Based on a comparison of percent acetylation (per microgram of protein
extract) after cotransfection with pEBV-MIE versus cotransfection with
pHD1013. Experiments 1 and 2 were performed in Loukes cells, and exper-
iment 3 was done in Raji cells.
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BMLF1 gene product. Somewhat surprisingly, the activity
of the negative control plasmid, pCAT3M, which contains
the CAT gene but no eucaryotic promoter element, was also
increased by cotransfection with BMLF1. The effects of the
BMLF1 transactivator were similar in the latently infected
Raji cells and the EBV-negative Loukes cells. The increase
in CAT activity produced by the BMLF1 gene product was
consistently greater when BMLF1 was cotransfected with
the three latent promoter plasmids (pW-CAT, pC-CAT, and
pLMP-CAT) or the pM-CAT plasmid versus the other EBV-
CAT plasmids (pZ-CAT, pEA-CAT, and pLate-CAT). How-
ever, the BMLF1 transactivator nonspecifically increased
the activity of both latent and productive EBV promoters
linked to CAT.
The BMLF1 transactivator does not significantly affect
mRNA levels. We demonstrated previously that the BMLF1
transactivator effect on pHIV-CAT activity is more than its
effect on pHIV-CAT mRNA (22). In this study, we analyzed
the effect of the BMLF1 transactivator on the level of RNA
produced by two different EBV promoters. To perform S1
nuclease analysis, a 32P-labeled RNA probe complementary
to pLate-CAT mRNA was generated by using SP6 polymer-
ase. The pM-CAT plasmid (5 ,ug) was cotransfected into Raji
cells with 5 ,ug of either the pHD1013 vector DNA or
pEBV-MIE. Cytoplasmic RNA was prepared from each
condition 48 h after transfection, hybridized to the 32p_
labeled RNA probe, and digested with S1 nuclease, and the
Si nuclease-protected fragment was run on an acrylamide-
urea gel. A sample of cells from each condition was also
analyzed for CAT activity. We used the pLate-CAT probe to
quantitate pM-CAT RNA so that any increase in CAT RNA
could be detected in this experiment regardless of whether
this RNA originated from the EBV promoter or a cryptic
plasmid promoter.
The Si nuclease results are shown in Fig. 2. In the
experiment shown, the pEBV-MIE transactivator increased
the level of CAT activity produced by pM-CAT by 20-fold.
However, this increase in CAT activity was not accompa-
nied by a similar increase in steady-state level of CAT
mRNA. Since the pCAT3M plasmid is also affected by
cotransfection with BMLF1, one explanation for our inabil-
ity to detect a significantly increased level of CAT mRNA
could have been that in the presence of BMLF1 most of the
CAT mRNA is initiating from a cryptic plasmid promoter,
rather than the authentic EBV promoter. However, this
explanation is unlikely since the total amount of CAT mRNA
(regardless of start site) is not influenced by the presence or
absence of the BMLF1 transactivator.
In addition to Si nuclease analysis, we used the primer
extension method to examine the effect of the BMLF1
transactivator on the level of CAT mRNA initiating at the
correct start site (Fig. 3). In the first experiment, the
pC-CAT plasmid (5 ,ug) was cotransfected into Raji cells
with either the phD1013 vector or the pEBV-MIE plasmid.
Cytoplasmic RNA was harvested at 24 h and hybridized with
a 32P-labeled oligonucleotide sequence homologous to the
CAT gene in the region 66 to 85 bp downstream of the ATG
codon, and primer extension was performed. The pC-CAT
mRNA was shown to originate from the expected start site
(lane A), and cotransfection with pEBV-MIE did not alter
the pC-CAT start site or increase the level of CAT mRNA
(lane B).
In a second experiment, the pS-CAT plasmid was cotrans-
fected into Jurkat cells with the phD1013 vector (lane C), the
pEBV-MIE plasmid (lane D), or plasmid pEBV-RIE, which
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FIG. 2. Si nuclease analysis of CAT mRNA. A 5-p.g portion of
the pS-CAT plasmid was cotransfected with 5 ,ug of either the
phD1013 vector or pEBV-MIE. Two days after transfection, a
sample of each was analyzed for CAT activity, demonstrating a
20-fold increase in CAT activity after cotransfection with pEBV-
MIE. Cellular RNA was prepared from the remainder of the cells. A
35-,ug amount of RNA was hybridized overnight with a 32P-labeled
antisense LATE-CAT RNA probe and then digested with S1 nucle-
ase. Since the probe and the pM-CAT construct are homologous
only in the CAT-encoding sequences, the protected RNA includes
CAT transcripts originating from all potential upstream start sites.
mic RNA was hybridized with a primer homologous to the
CAT gene sequence 15 to 34 bp downstream of the ATG
codon. The pS-CAT mRNA was shown to originate from the
expected start site (lane C). Once again, cotransfection with
the BMLF1 transactivator did not affect the level of CAT
mRNA, in spite of a large increase in CAT activity (lane D),
whereas the BRLF1 transactivator clearly increased CAT
mRNA in the same experiment (lane E). The pS-CAT (rather
than pM-CAT) construct was used in the primer extension
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FIG. 3. Primer extension analysis of CAT mRNA. Primer exten-
sion analysis was used to determine the effect of the BMLF1
transactivator on mRNA originating from the expected start site. In
the first experiment, the pC-CAT plasmid was cotransfected into
Raji cells with either the phD1013 vector (lane A) or the pEBV-MIE
plasmid (lane B). Cytoplasmic RNA was hybridized with a y-
32P-labeled primer homologous to the CAT gene sequences 64 to 85
bp downstream of the ATG codon, and primer extension was
performed. The expected primer extension product from pC-CAT is
125 bp. Cotransfection with pEBV-MIE had no effect on the level of
pC-CAT mRNA or the use of the start site. In the second experi-
ment, the pS-CAT plasmid was cotransfected into Jurkat cells with
the phD1013 vector (lane C), the pEBV-MIE plasmid (lane D), or a
plasmid encoding the EBV BRLF1 transactivator (lane E). In this
experiment, CAT mRNA was hybridized to a primer homologous to
the CAT sequences 15 to 34 bp downstream of the ATG codon, and
the expected primer extension product is 170 bp. Cotransfection
with the BRLF1 transactivator resulted in an increase in the CAT
mRNA (lane E), whereas the BMLF1 transactivator had no effect
(lane D).
experiment since the pS-CAT plasmid contains additional
3'-promoter sequences, including the endogenous cap site.
The CAT activity produced by the pS-CAT and pM-CAT
constructs was shown to be identical in numerous cell types
(data not shown).
The BMLF1 transactivator is reporter-gene dependent. To
determine the plasmid sequences required for transactiva-
tion by the BMLF1 gene product, we systematically re-
moved different portions of the pM-CAT plasmid and tested
for the ability of the resultant plasmids to respond to the
BMLF1 transactivator.
The results of these experiments are summarized in Table
3. As already shown by the previous set of data, the EBV
promoter element in pM-CAT is not required for transacti-
vation by BMLF1, since pCAT3M (which removes the EBV
promoter) is also transactivated. To determine whether the
BMLF1 transactivator is specifically recognizing a cryptic
promoter element within the pCAT3M vector sequences, we
built two plasmids (pC-PUC9A and C-PUC9B) which re-
move the CAT gene and the SV40 polyadenylation signal
from the pBR322 vector and placed these sequences into the
PUC-9 vector in either orientation (A or B). Since both of the
TABLE 3. Analysis of pM-CAT sequences required for
transactivation by BMLF1 gene product
Plasmid Promoter Vector Reporter Poly(A) Transacti-vation
pM-CAT BMLF1 pBR322 CAT + +
pCAT3M None pBR322 CAT + +
pC-PUC9A" None PUC-9 CAT + +
pC-PUC9B" None PUC-9 CAT + +
pM_C_PUC9+b BMLF1 PUC-9 CAT + +
pM_C_PUC9-b BMLF1 PUC-9 CAT - +
pM-GH' BMLF1 PUC-12 GH + -
" pC-PUC9A and pC-PUC9B have the CAT reporter gene and SV40
polyadenylation sequences in a PUC-9 vector (in either orientation A or B)
with no eucaryotic promoter element.
b pM-C-PUC9+ and pM-C-PUC9- have the BMLF1 promoter driving the
CAT gene in a PUC-9 vector, the only difference between the two plasmids
being the presence or absence of the SV40 polyadenylation sequences.
C pM-GH has the BMLF1 promoter inserted upstream of the human growth
hormone gene in the pGH vector (40).
resultant plasmids responded equally well to the BMLF1
transactivator, it seems unlikely that the BMLF1 transacti-
vator recognizes a specific promoter element within either
the pBR322 or the PUC-9 sequences. To exclude the possi-
bility of a response region within the SV40 polyadenylation
sequences, we built two plasmids (pM-C-PUC9+ and pM-
C-PUC9-) which are identical except for the presence or
absence of the SV40 polyadenylation sequence. The SV40
polyadenylation sequence proved not to be required for
response to BMLF1, since the M-C-PUC9- plasmid (which
has no SV40 polyadenylation site) still responds to the
BMLF1 transactivator.
Finally, to exclude a responsive region within the CAT
gene itself, we replaced the CAT gene with another reporter
gene, the human growth hormone gene (40), and named this
plasmid pM-GH. Table 4 shows the results of several dif-
ferent growth hormone experiments with either pM-GH or
pC-GH (which has the BamHI-C promoter linked to the
growth hormone gene). In each of these experiments, pM-
GH and pM-CAT (or pC-GH and pC-CAT) were cotrans-
fected into the same cells with the phD1013 vector, the
pEBV-MIE construct, pEBV-ZIE (which has the EBV
BZLF1 transactivator) (21), or phD101SV1 (which has the
cytomegalovirus IE transactivator) (9). Three days after
transfection, the cells were harvested for CAT activity,
while the supernatant fluid was analyzed for growth hor-
mone activity by using a radioimmunoassay (40). The simul-
taneous analysis of the effect of BMLF1 on both CAT and
growth hormone activities within the same cells was facili-
tated by the fact that, whereas CAT activity is contained
within cells, growth hormone is secreted into the media. The
extreme sensitivity of the growth hormone assay used (Al-
legro HGH) allows reproducable detection of as little as 0.06
ng of human growth hormone per ml.
In each experiment the CAT activity produced by pM-
CAT or pC-CAT was significantly increased by cotransfec-
tion with BMLF1 (Table 4), whereas the growth hormone
activity produced by the identical promoter was not in-
creased by cotransfection with BMLF1. On the other hand,
the pM-GH plasmid responded as expected to the EBV
BZLF1 transactivator. Likewise, the pC-GH plasmid re-
sponded to the cytomegalovirus IE transactivator. When
cellular extracts (instead of supernatant fluids) were ana-
lyzed for growth hormone activity, there was still no stimu-
lation observed with the BMLF1 transactivator. We have
recently observed that an additional reporter gene, gal, is
J. VIROL.
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TABLE 4. Effect of different transactivators on CAT versus growth hormone reporter genes
CAT activity' Growth hormoneb
Expt Plasmid Transactivator Constitutive Transactivator Fold Constitutive Transactivator Fold
(%) (%) increase (ng/ml) (ng/ml) increase
1 pM-GH/pM-CAT pEBV-MIE 2.08 10.84 5 0.2 0.1 <1
pEBV-ZIE 2.08 14.39 7 0.2 1.4 7
2 pM-GH/pM-CAT pEBV-MIE 2.30 10.36 5 0.1 0.1 1
pEBV-ZIE 2.30 16.02 7 0.5 0.5 5
3 pC-GH/pC-CAT pEBV-MIE 2.0 58.20 29 0.1 0.1 1
pHD1O1SV1 2.0 32.40 16 0.1 1.7 17
4 pC-GH/pC-CAT pEBV-MIE 1.18 19.91 17 0.4 0.1 <1
a All experiments were performed in B95-8 cells. CAT activity is expressed as percent acetylation produced per 10 ,ug of protein extract.
b Growth hormone activity secreted into the media was measured by using radioimmunoassay (40), while CAT activity was measured in cellular extracts from
the same experiment.
also unresponsive to the BMLF1 transactivator (D. Marko-
vitz et al., unpublished data).
DISCUSSION
The differential regulation of viral promoters expressed
during latent versus productive EBV infection may be a key
element in governing the switch from the latent to the
productive state. A major objective of the present work was
therefore to determine whether the EBV BMLF1 transacti-
vator could specifically activate a particular class of EBV
promoter. Our own work, and that of others, had previously
indicated that certain promoters linked to the heterologous
bacterial CAT gene can be activated by cotransfection with
the BMLF1 gene product (7, 22, 30, 45). Somewhat surpris-
ingly, further study has in fact demonstrated that the primary
effect of the BMLF1 transactivator appears to be directed at
the CAT gene itself, with the role of the promoter being, at
most, secondary. Therefore, the BMLF1 "transactivator" is
unlikely to activate a specific promoter(s) in EBV and more
likely functions to increase the level of an unidentified viral
or cellular protein.
Our finding that the BMLF1 transactivator does not sig-
nificantly increase the level of CAT mRNA suggests a
posttranscriptional mechanism. In addition, the reporter-
gene dependence of the BMLF1 transactivator also argues
for a posttranscriptional mechanism, since any transcrip-
tional effect would be expected to be independent of the
reporter gene used. At this point, however, we do not know
whether the effect of BMLF1 is to stabilize CAT mRNA, to
increase its translational efficiency, to stabilize the CAT
protein itself, or to increase CAT enzyme efficiency. Since
the increase in CAT activity produced by cotransfection
with the BMLF1 gene product is sometimes accompanied by
a small increase in mRNA (22) (although this CAT mRNA
increase is less than the increase in CAT activity), it is
possible that the BMLF1 gene product acts to stabilize CAT
mRNA. Conceivably, a very small difference in CAT mRNA
stability might result in much larger differences in CAT
activity, if the CAT mRNA is very unstable and CAT protein
is particularly stable. However, the inability of the BMLF1
gene product to activate the growth hormone constructs
suggests that any such effect on mRNA stability would have
to be limited to a certain subset of host or viral RNAs.
Alternatively, the BMLF1 transactivator might enhance
translation of CAT mRNA. Again, this effect would have to
be limited to a certain subset of viral or cellular mRNAs. A
third possibility is that the BMLF1 gene product stabilizes
the CAT protein itself or increases the enzymatic activity of
the CAT protein. The consistent differences in the response
of each of the EBV-CAT constructs to the BMLF1 effect
(i.e., the relatively low responses of the pLate-CAT and
pEA-CAT constructs versus the very high response of the
pC-CAT and pLMP-CAT constructs) suggest that the EBV
insert sequences have some effect on the ability of the CAT
gene to respond to the BMLF1 transactivator. This effect of
insert sequences suggests that the function of BMLF1 is
more likely to occur at the level of RNA stability or
translational efficiency, since EBV insert sequences would
be less likely to influence CAT protein stability or enzyme
function. We are currently in the process of determining by
which mechanism BMLF1 gene product increases CAT
activity.
In any event, our finding that the BMLF1 transactivator is
reporter-gene dependent has clear relevance to other inves-
tigators employing the "CAT assay" to study promoter
regulation. The BMLF1 effect is directed at the CAT gene
itself, rather than the promoter, and there are likely to exist
other viral or cellular gene products which can use a similar
mechanism to affect CAT activity. Therefore, it is prudent to
use at least two different reporter genes before concluding
that an observed increase in CAT activity is necessarily due
to an effect on promoter activity.
Previous investigators have shown that the BMLF1 gene
product is of heterogeneous size (molecular weights, 45,000
to 70,000), with the major product being a phosphorylated
60-kilodalton protein that localizes to the nucleus (32, 46). At
this point, the role of the BMLF1 gene product in EBV
infection remains unknown. Clearly, the purpose of this gene
in EBV infection is not directed at affecting the activity of
the bacterial protein CAT. The effect of BMLF1 on the CAT
activity may be entirely fortuitous and may not relate to the
mechanism by which the BMLF1 IE gene product presum-
ably promotes EBV productive infection. Nevertheless, it is
tempting to speculate that the BMLF1 gene product might
also increase the level of cellular or viral protein(s) required
for viral infection by using the same mechanism by which it
increases CAT activity.
Previously, the BMLF1 transactivator has been described
as "promiscuous" (30). However, since all previous studies
examining the effect of BMLF1 on different promoters have
used CAT vectors, it is now clear that BMLF1 may not be
promiscuous at all in its effect; rather, the CAT gene may
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fortuitously resemble in some aspect the intended target
gene(s) of BMLF1. We believe that the reporter-gene depen-
dence and posttranscriptional mechanism of BMLF1 make it
an extremely novel regulatory protein. It will now be impor-
tant to determine the intended target gene(s) of the BMLF1
gene product.
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